GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskriftPeer review

35 !!Citations (SciVal)

Sammanfattning

Glucagon-like peptide-1 (GLP-1)-based therapy is a novel treatment for type 2 diabetes. It is executed either by GLP-1 mimetics or by dipeptidyl peptidase-IV inhibitors. In type 2 diabetes, the two strategies reduce hemoglobin A(1c) by 0.6% to 1.1% from baseline levels of 7.7% to 8.5%. They are efficient both in monotherapy and in combination with metformin or thiazolidinediones. Both treatments are well tolerated with low risk of hypoglycemia.
Originalspråkengelska
Sidor (från-till)340-347
TidskriftCurrent Diabetes Reports
Volym7
Utgåva5
StatusPublished - 2007

Ämnesklassifikation (UKÄ)

  • Endokrinologi och diabetes

Fingeravtryck

Utforska forskningsämnen för ”GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.”. Tillsammans bildar de ett unikt fingeravtryck.

Citera det här